Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Phase 1 Completed 31 enrolled Novo Nordisk A/S

RandomizedParallel-groupDouble-blindTreatment

Summary

This trial is conducted in the United States of America (USA). The aim of this trial is to investigate the safety, tolerability and pharmacokinetics (exposure in the body) of liraglutide-depot in healthy subjects.

Timeline

Start: 2011-10
Primary completion: 2012-03
Completion: 2012-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Liraglutide	Peptide	2.25 mg	Subcutaneous
Subject	Liraglutide	Peptide	6.75 mg	Subcutaneous
Subject	Liraglutide	Peptide	15 mg	Subcutaneous
Subject	Liraglutide	Peptide	30 mg	Subcutaneous

Safety, Tolerability and Pharmacokinetics of Liraglutide-depot in Healthy Subjects

Summary

Timeline

Drugs

Indications